The United Kingdom has launched the world's first clinical trial for a personalised cancer vaccine.
Unlike traditional vaccines that prevent disease, this immunotherapy targets patients with existing tumours, teaching their immune systems to identify, attack, and prevent the spread of cancer cells.
Through the new Cancer Vaccine Launch Pad, thousands of cancer patients in England will gain fast-tracked access to tailored treatments.
If successful, the trial could pave the way for a significant reduction in global cancer rates, with up to 10,000 patients expected to receive bespoke therapies by 2030.
